Chengdu Kanghong Pharma 
Welcome,         Profile    Billing    Logout  
 3 Products   3 Diseases   3 Products   28 Trials   310 News 


«123456789»
  • ||||||||||  Lumitin (conbercept) / Chengdu Kanghong Biotech
    Journal:  Combined Anti-Angiogenic and Anti-Inflammatory Nanoformulation for Effective Treatment of Ocular Vascular Diseases. (Pubmed Central) -  Feb 1, 2023   
    CBC-MCC@hMSN(SM) complex nanoformulation was prepared by integrating conbercept (CBC, an anti-angiogenic drug) and MCC950 (MCC, an inhibitor of inflammation) into the surface-modified hollow mesoporous silica nanoparticles (hMSN(SM))...A single intraocular injection of CBC-MCC@hMSN(SM) complex potently suppressed diabetes-induced retinal vascular dysfunction, choroidal neovascularization, and inflammatory responses for up to 6 months. Combined CBC and MCC nanoformulation provides a promising strategy for sustained suppression of pathological angiogenesis and inflammatory responses to improve the treatment outcomes of ocular vascular diseases.
  • ||||||||||  KH617 / Chengdu Kanghong Pharma
    Trial initiation date, Metastases:  Phase 1 Trial of KH617 (clinicaltrials.gov) -  Jan 19, 2023   
    P1,  N=45, Recruiting, 
    High-risk PDR patients treated with IVC + PRP showed a higher rate of NV regression, more effective improvement in the BCVA, and lower vitrectomy rate compared to those who were administered PRP monotherapy. Initiation date: Dec 2023 --> Dec 2022
  • ||||||||||  KH617 / Chengdu Kanghong Pharma
    New P1 trial, Metastases:  Phase 1 Trial of KH617 (clinicaltrials.gov) -  Dec 28, 2022   
    P1,  N=45, Recruiting, 
  • ||||||||||  Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis, Lumitin (conbercept) / Chengdu Kanghong Biotech
    Retrospective data, Review, Journal:  The Male to Female Ratio in Treatment-Warranted Retinopathy of Prematurity: A Systematic Review and Meta-analysis. (Pubmed Central) -  Nov 22, 2022   
    This could be due to a known relative pathophysiological fragility of preterm male infants in addition to a difference in ROP screening rates, with more male infants meeting the criteria than female infants. These findings have implications for future studies and may prompt more careful clinical monitoring of male neonates.
  • ||||||||||  Lumitin (conbercept) / Chengdu Kanghong Pharma
    Enrollment change, Trial completion date, Trial termination:  Effects of Conbercept in Refractory Uveitic Macular Edema and VEGF (clinicaltrials.gov) -  Oct 25, 2022   
    P2/3,  N=5, Terminated, 
    The data suggest that a greater number of anti-VEGF injections was associated with better improvement in BCVA and moderate reduction in retinal thickness at the 1-year follow-up. N=18 --> 5 | Trial completion date: Oct 2020 --> Feb 2022 | Unknown status --> Terminated; Due to inter-city travel restrictions for COVID-19, regular follow-up for most patients is not possible
  • ||||||||||  Lumitin (conbercept) / Chengdu Kanghong Biotech
    Journal:  Factors associated with the recurrence of choroidal neovascularization in pathologic myopia. (Pubmed Central) -  Oct 1, 2022   
    Forty-eight eyes of 48 patients with PM-CNV treated with conbercept at least 6 months of follow-up were included...Baseline BCVA and clinical features play an important role for vision prognosis. Factors associated with PM-CNV recurrence include HRF height, CNV area, and changes in EZ and RPE structure.
  • ||||||||||  Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis, Lumitin (conbercept) / Chengdu Kanghong Biotech
    Treat-and-Extend Versus As-Needed Regimen in Neovascular Age-Related Macular Degeneration: 1-Year Findings From a Network Meta-Analysis (Virtual) -  Sep 1, 2022 - Abstract #ISPOREU2022ISPOR_EU_1895;    
    We included RCTs of anti-VEGF drugs (intravitreal aflibercept [IVT-AFL], intravitreal ranibizumab [IVR], and intravitreal conbercept [IVC]) using a T&E or PRN regimen for patients with nAMD... Different anti-VEGF regimens may provide similar visual benefits following 1 year of treatment, whereas IVT-AFL T&E (with either 2- or 4-week adjustments) may reduce injection burden for patients with nAMD.
  • ||||||||||  Lumitin (conbercept) / Chengdu Kanghong Biotech
    Biomarker, Retrospective data, Journal:  Prognostic Factor Study of Macular Edema Recurrence in Retinal Vein Occlusion after Conbercept Treatment: A Post Hoc Analysis of the FALCON Study. (Pubmed Central) -  Aug 10, 2022   
    In addition, logistic regression analyses indicated the corrections of ME recurrence with baseline macular volume and the disruption of the outer limiting membrane at the fovea. This study suggested that OCT parameters, including baseline macular volume and outer limiting membrane disruption, and reduction in CRT after loading therapy were more predictive of ME recurrence than FA patterns or visual changes following conbercept loading therapy.
  • ||||||||||  Lumitin (conbercept) / Chengdu Kanghong Pharma
    Trial completion:  CRVO: Conbercept Ophthalmic Injection for Patients of Central Retinal Vein Occlusion (clinicaltrials.gov) -  Jul 13, 2022   
    P3,  N=242, Completed, 
    This study suggested that OCT parameters, including baseline macular volume and outer limiting membrane disruption, and reduction in CRT after loading therapy were more predictive of ME recurrence than FA patterns or visual changes following conbercept loading therapy. Unknown status --> Completed
  • ||||||||||  Retrospective data, Review:  Different Anti-Vascular Endothelial Growth Factor for Patients With Diabetic Macular Edema: A Network Meta-Analysis. (Pubmed Central) -  Jul 13, 2022   
    We included RCTs of anti-VEGF drugs (intravitreal aflibercept (IVT-AFL), intravitreal ranibizumab (IVR), and intravitreal conbercept (IVC)) treating adult patients who were diagnosed with DME, regardless of stage or duration of the disease...The effect of improvement in BCVA was identified for IVT-AFL compared to intravitreal bevacizumab...After two years, there was insufficient evidence to identify which anti-VEGF has superior efficacy or safety. Clinical Trial Registration: https://www.crd.york.ac.uk/prospero/, PROSPERO; https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42021259335, CRD42021259335.
  • ||||||||||  Lumitin (conbercept) / Chengdu Kanghong Biotech
    Journal:  A Randomized, Controlled Trial of Treat-and-Extend vs. Pro Re Nata Regimen for Neovascular Age-Related Macular Degeneration. (Pubmed Central) -  Jul 8, 2022   
    P4
    To compare the efficacy and safety of conbercept using a treat-and-extend (T&E) regimen vs. a pro re nata (PRN) regimen in Chinese patients with neovascular age-related macular degeneration (nAMD)...These findings suggest that the T&E regimen was not non-inferior to the PRN regimen in patients with nAMD in terms of BCVA outcomes through 24 months. ClinicalTrials.gov, identifier NCT02802657.
  • ||||||||||  Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis, Lumitin (conbercept) / Chengdu Kanghong Biotech
    Journal:  New trends in intravitreal anti-VEGF therapy for ROP. (Pubmed Central) -  May 19, 2022   
    The recurrence rate stands at an average of 28.9%, especially in the later forms of ROP. Using a dose of 0.25 mg of Conbercept, the disease regression rate is currently on average 83%, with an average recurrence rate of 15.24%, the peak of which was observed in cases of ROP in zone I. Further studies are needed to prove safety at long term, because,at the moment, only short-term data are available.
  • ||||||||||  Clinical, Review, Journal:  Next-generation anti-VEGF agents for diabetic macular oedema. (Pubmed Central) -  Apr 19, 2022   
    In this manuscript, we cover pharmacodynamics, preliminary results from clinical trials, and safety behavior about brolucizumab, faricimab, conbercept, KSI-301, and port-delivery system WR42221. These treatments might present the first step to control the global epidemic of diabetic eye disease in real life.
  • ||||||||||  Lumitin (conbercept) / Chengdu Kanghong Biotech
    Journal:  Analysis on short-term change of macular function and the correlates after intravitreal conbercept for CRVO-ME. (Pubmed Central) -  Apr 17, 2022   
    These treatments might present the first step to control the global epidemic of diabetic eye disease in real life. The BCVA、the structure and the function of macular were greatly improved after intravitreal conbercept for central retinal vein occlusion induced macular edema; however no significantly correlation between the improvement of the function of macular with the strcture of macular and BCVA.